Novavax, Inc. (NASDAQ: NVAX) reported Q4 EPS of ($0.07), $0.01 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Earnings

Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM)March 10, 2014 4:14 PM